ArticleMethods in molecular biology (Clifton, N.J.)2025
Large-Scale Production of Unmodified mRNA for Reprogramming Human Dendritic Cells and T Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Harnessing the potential of mRNAs to express proteins of interest has emerged as a powerful tool in biotechnology and medicine, particularly in the development of vaccines. Such mRNAs can be in-vitro transcribed (IVT) in a controlled laboratory environment using a DNA template that encodes the protein of interest. Key components required include the DNA template, T7 RNA polymerase, ribonucleoside triphosphates, and necessary cofactors. The resulting mRNA is then purified and can be loaded directly into target cells ex vivo or formulated into lipid nanoparticles for in vivo delivery as, e.g. a vaccine. IVT-produced mRNA vaccines offer rapid development, high efficacy, and a versatile platform, as demonstrated by the success of COVID-19 vaccines. In this chapter, we describe the production and purification of unmodified IVT mRNA for ex vivo generation of dendritic cell (DC) mRNA vaccines or T cells engineered with chimeric antigen receptors.
Indexed as
Identifiers
40877507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.